News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News VIVA 2023 ‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion L.A. McKeown November 03, 2023
News Conference News VIVA 2022 ‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups L.A. McKeown November 04, 2022
News Conference News VIVA 2021 Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI L.A. McKeown October 08, 2021
News Conference News VIVA 2021 Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis L.A. McKeown October 06, 2021
News Conference News VIVA 2020 As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice L.A. McKeown November 27, 2020
News Conference News VIVA 2019 Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions L.A. McKeown November 13, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News VIVA 2018 Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention L.A. McKeown November 09, 2018
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News VIVA 2016 Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions L.A. McKeown September 22, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016